Record growth & margin beat; CDMO at inflection point ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Hit EBITDA guidance and beat margins. CDMO USD100M target achieved earlier than planned. Specialty Chemicals tracking to ₹350Cr+ target.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Navin delivered a strong H1 with 57% revenue growth and 34.2% EBITDA margins (beating guided 32–33% ±1%), supported by HPP ref gas pricing, Specialty Chemicals momentum, and CDMO at inflection (USD100M run-rate target hit early). Long-term outlook is compelling: multiple molecule FDA readouts expected, Advanced Materials ₹90Cr capex to commercialize 4–5 products, and ₹350Cr+ Specialty Chemicals scale. Key near-term risk: geopolitical volatility and capex intensity (₹700–1,000Cr annually) will pressure FCF; hold until CDMO Phase 2 capex cadence clarifies and first FDA readouts land.
₹1190.7 Cr
Revenue · +57% YoY₹269.2 Cr
Reported PAT · +81.5% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
EBITDA margins 34.2%, beating guidance range
METH1 EBITDA margin 34.2% vs prior guidance 32–33% ±1%
CDMO USD100M run-rate target, achieved earlier than initially planned
METTranscript confirms USD100M by FY27 on run-rate, now flagged as early
All three segments delivered sequential momentum
METHPP ref gas pricing advantage + volume, Specialty Chemicals growth, CDMO encouraged developments
Gross profit resilience despite cost inflation
METOPM 34.2% sustained via forex tailwind + pricing actions offsetting sourcing inflation
Earnings quality
What changed since the last call
CDMO scale-up pace
UpgradeUSD100M run-rate target hit in Q2 FY27 (earlier than planned). Phase 2 cGMP-4 capex (₹125 Cr) progressing for commissioning by end Q4 FY27.
Specialty Chemicals ramp
Upgrade₹350Cr+ annual run-rate now targeted for FY27 end (vs. prior commentary of 'growth business'). PAR exceeding prior benchmarks on product mapping & molecule volume.
Soltice HFO contract
UpgradeExtended 4-year contract now 11-year visibility to 2032; USD180M potential vs. prior USD58M annual run rate. Pricing mechanism pass-through; market dynamics (advanced cooling) underpinning upside.
Capex frame transparency
NewDefined ₹700–1,000 Cr annual capex envelope with multi-year line-of-sight (Phase 2, Advanced Materials, DRDO, etc.). Projects will be stage-gated; no formal guidance on final capex yet.
The Q&A
Analysts probed margin sustainability (inflation, sourcing), CDMO molecule timelines, Chemours project delays, and capex intensity. Management held firm: margins defended on operational efficiency + pricing power; CDMO delays are strategic (right process, not a miss); geopolitical risks flagged but navigable. Analysts broadly impressed; limited skepticism on execution risk.
Revenue bridge & segments — Sanjesh Jain, ICICI Securities
AnsweredHPP: pricing advantage + ref gas volume. Specialty Chemicals: orchid & Corteva growth. CDMO: new molecule campaigns + Fermion base. All helping sequential ramp.
HFO contract extension — Rohit Nagraj, 360 ONE Capital
Answered7-year avg was USD60–odd million; next 4 years USD45M (pricing pass-through mechanism). Extension adds USD180M potential; both volumes & pricing will increase over time.
CDMO Phase 2 & molecules — Ankur Periwal, Axis Capital
AnsweredPhase 1 & 2 both Fermion-dedicated. 2 molecules in advanced stage; 1 China-approved, on fast track FDA. Others at label-expansion stage. 3–4 FDA readouts expected next 8–12 months.
Chemours specialty material (DRDO) — Archit Joshi, Nuvama Wealth
AnsweredDelay is strategic (right process, not reactive). Pilot-scale to initial capacity involves different process routes. Already have orders for future quarters; dual-use potential (pharma ₹400Cr market + defense).
CDMO USD100M & capex plans — Arun Prasath, Avendus Spark
AnsweredUSD100M by FY27 on track. Phase 2 capex with full warehouse & ETP infra can reach cGMP-5 quickly. Peak annual revenue close to 3x capital (INR900–1,000Cr by FY28–29). Capex frame ₹700–1,000 Cr annually.
Margins durability — Sanjesh Jain, ICICI Securities (follow-up)
AnsweredForex tailwind + pricing actions offset sourcing inflation. Operating leverage (MPP debottlenecking, R32 ramp, AHF on play) also key. EBITDA 34% is sustainable on efficiency, not just pricing.
Specialty Chemicals PAR & capex — Sanjaya Satapathy, Ampersand Capital
AnsweredNo shift; building on what we have. Specialty Chemicals ₹350Cr+ by FY27 end. Advanced Materials 10–15% of pie by 2030 (₹90Cr capex to Q2 FY28). Next 5 years growth baked into capex plan.
HFO utilization & pipeline — Jason Soans, IDBI Capital
AnsweredUtilization will improve. Demand upside from construction (cooling) & chillers sectors. HFO is premium product, greener. Expected demand to rise; some material also serving high-purity end use.
HFO pricing & patent dynamics — Ranjit, IIFL Capital
AnsweredHFO is premium product (greener, 10% of global ref gas capacity). Patent expiry affects generics; Soltice is different application, evergreen product. Pricing power comes from end-use superiority, not patent alone.
Guidance
FY27 EBITDA margins 32–33% ±1% (prior)
HighH1 delivered 34.2%, beating upper end. Management reaffirms long-term 30%+ sustainable; no formal change announced this call.
CDMO USD100M run-rate by FY27 end
HighAchieved in Q2 on run-rate basis, earlier than planned. Phase 2 capex (₹125 Cr) to scale capacity further.
EBITDA margin 34% long-term; near-term 'in same sort of range'
MediumManagement cautious on far-future due to geopolitical volatility. FY27 margins to stay in range of H1 (34.2%) for full year, with some normalization in H2.
Annual capex ₹700–1,000 Cr; H1 FY27 ₹300–310 Cr spent
HighPhase 2 cGMP-4 (₹125 Cr), Advanced Materials adoption (₹90 Cr), R32 capex, and other projects. Stage-gated; future capex to be announced as projects mature.
Risks the call surfaced
Geopolitical volatility
MediumRussia-Ukraine, Middle East tensions impact fluorine, HF, and refrigerant supply routes. Demand for industrial refrigerants sensitive to global capex cycles.
Customer concentration
MediumCorteza & Soltice are material customer relationships for HPP ref gases. Loss of either could impact ₹400–500 Cr+ revenue.
Raw material inflation
MediumHF, fluorspar, sulfuric acid prices have risen. If pricing power weakens (e.g., ref gas prices soften), margins could compress below 30% EBITDA.
Capex execution risk
Medium₹700–1,000 Cr annual capex required through FY28. Delays in Phase 2 cGMP-4 or Advanced Materials adoption could defer growth & cash generation.
CDMO molecule FDA approval timing
Medium3–4 FDA readouts expected in next 8–12 months. Delays or negative outcomes could slow CDMO revenue ramp beyond USD100M.
Management
Score 8/10. Clear and granular. Anish (CFO) provided segment-by-segment breakdown, capex frame, CDMO timelines, and margin drivers. Addressed evasive points (Chemours delay, HFO pricing) with candor; acknowledged geopolitical risks but conveyed navigability. Strong. Hit EBITDA guidance and beat margins. CDMO USD100M target achieved earlier than planned. Specialty Chemicals tracking ₹350Cr+ ambition. Capex commissioning (debottlenecking, R32) on schedule. No major misses flagged.
1 · Q3 FY27
HFC ref gas volumes from Corteva demand; R32 plant full commissioning
2 · Q4 FY27
MPP debottlenecking yield, specialty molecules campaign orders ramp
3 · H2 FY27
First FDA readouts on CDMO molecule pipeline (1–2 of 3–4 expected)
Key near-term risk: geopolitical volatility and capex intensity (₹700–1,000Cr annually) will pressure FCF; hold until CDMO Phase 2 capex cadence clarifies and first FDA readouts land.
Expect strong momentum continuation as debottlenecking ramps
After Q1's 44% revenue jump and doubled PAT, the Street watches for sustained growth momentum in Q2 as new capacity comes online. A DRDO partnership and captive power capex signal strategic depth, but execution on margin expansion will be the real test.
The Setup
What to expect: Navin Fluorine enters Q2 FY27 with significant momentum. Q1 delivered ₹1,045.08 Cr consolidated revenue (44.1% YoY, 11.4% QoQ) and consolidated PAT of ₹243.31 Cr—more than doubling year-on-year. The Street will be watching for sustained mid-to-high 30s% growth in the new quarter as the Multi-Purpose Plant (MPP) debottlenecking capacity, commissioned in late September, begins to feed volume. Margins matter equally: Q1's PAT% expansion signals pricing/mix power, and Q2 estimates hinge on whether that sticks as new capacity ramps and input costs stabilize.
~₹1,000–1,100 Cr
On-plan growth trajectory; Q1 grew 44% YoY to ₹1,045 Cr
~23–24%
Q1 delivered strong PAT expansion; Street watches for sustenance vs input/FX headwinds
₹90 Cr approved
Board approved in Q1; ₹3.63 Cr additional for captive power; medium-term capacity story intact
MPP ramp-up
Debottlenecking live Sep 29; DRDO Sodium Borohydride partnership adds specialty segment opportunity
On Track to Guidance?
Full-year FY27 guidance has not been explicitly disclosed in the filings. However, the Q1 beat and operational momentum (MPP commissioning, capex authorization, DRDO partnership) suggest management is executing to an internal plan. The run-rate—₹1,000+ Cr quarterly revenue with 23%+ PAT margin—would imply an FY27 operating profit pool in the ₹950–1,000 Cr range, well ahead of FY26's levels. Street analysts expect FY27 EPS of ₹87.75, implying ~₹880–920 Cr consolidated PAT for the year; Q1's ₹243 Cr (annualizing to ~₹970 Cr) suggests the estimate may be conservative. The risk: if Q2 flattens sequentially or if the capex-driven growth story disappoints, the Street will need to reset.
What the Street Says
Since Last Quarter
Sep 29, 2026
MPP debottlenecking capacity commissioned
Volume growth catalyst; removes a previous constraint on specialty-chemical production
Sep 24, 2026
Board meeting scheduled for Oct 30; trading window closed
Routine; result announcement date confirmed
Aug 05, 2026
Q1 FY27 results announced; ₹90 Cr capex approved
Beat on revenue/PAT; medium-term expansion plan signals confidence
Jul 30, 2026
DRDO partnership: Sodium Borohydride manufacturing agreement
Strategic; adds defence/chemistry segment; recurring potential under government contract
Jul 27, 2026
₹3.63 Cr investment in Pro-Zeal captive power SPV
Operational efficiency play; reduces energy cost headwinds
Jul 06, 2026
SBI Mutual Fund acquires 5% stake
Institutional participation; DII/MF holding now ~29% (stable)
What to Watch on Result Day
1 · Margin print & guidance
If PAT% stays above 23%, the Street resets FY27 estimates upward; if it dips below 22%, the narrative shifts to cost headwinds. Any FY27 or FY28 guidance will matter more than the number itself.
2 · MPP ramp trajectory & new orders
Disclosure of Q2 volume uptake from debottlenecking, and any update on DRDO supply milestones or other defence/specialty orders will signal how durable the growth is.
3 · Capex spend & FY28 outlook
An update on the ₹90 Cr capex deployment (timeline, ROI targets) and any new capex announcements will tell you whether management is confident in sustained demand or preparing for a cycle slow.
Navin Fluorine set up the print with a clean Q1 beat and two structural catalysts—new capacity online and a DRDO partnership—that address the old critique of being a cyclical commodity play. The Street has moved; consensus targets are now ₹9,635 high, and three-quarters of analysts are bulls. The risk for Q2 is straightforward: prove the margins and the capex ROI, or watch the stock re-rate. For long-only holders, a beat and a confident FY27 outlook likely trigger the next leg. For value traders, the stock is down 14% from ATH—a miss could accelerate that.
Navin Fluorine Q2 FY27: consolidated PAT up 81% YoY to ₹269 Cr, margins top guidance
PAT +81.44% YoY · revenue +57% · margins expanding
₹1,190.74 Cr
+57% YoY
₹269.24 Cr
+81.44% YoY
22.32%
+3.2pp YoY
₹52.48
Navin Fluorine's consolidated revenue for Q2 FY27 (quarter ended September 30, 2026) came in at ₹1,190.74 Cr, up 57.0% YoY from ₹758.42 Cr and up 13.9% QoQ from ₹1,045.08 Cr. Consolidated PAT was ₹269.24 Cr, up 81.4% YoY from ₹148.37 Cr and up 10.7% QoQ from ₹243.31 Cr — profit growth continued to outrun revenue growth YoY, extending the pattern from Q1 FY27 (PAT +107.7% YoY). Basic EPS was ₹52.48 against ₹29.06 a year earlier. No exceptional items were recorded in either the current or year-ago quarter, so the growth is unadjusted/clean; the only one-off in the trailing record is a ₹6.75 Cr consolidated labour-code provision booked for the FY26 full year, outside both compared quarters.
Q2 FY-2027 vs prior quarters
OPM (EBITDA/revenue from operations) expanded to 34.2% from 32.46% a year ago, and held essentially flat against Q1 FY27's 34.17% — sitting at or just above the top of management's own FY27 guided band of "normalized EBITDA margins 32-33% ±1%" set out on the August 2026 Q1 concall, meaning the quarter met to slightly beat that outlook. NPM was 22.3%, up sharply from 19.1% YoY but down marginally from 22.5% in Q1, as other income normalized to ₹15.6 Cr from ₹35.1 Cr in Q1. Standalone PAT was ₹204.57 Cr on standalone revenue of ₹737.26 Cr; the gap to consolidated PAT of ₹269.24 Cr (roughly ₹65 Cr, about a quarter of group profit) reflects contribution from the foreign subsidiaries and the CDMO/Advanced Sciences units the company has been directing capex toward.
The stock went into the print at ₹8,544.5, up 3.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
FY27 normalized EBITDA margins 32–33% ±1% on HFC/MPP/Chemours capex. CDMO targeting 3x asset turn by FY'29 on ₹288 Cr Phase 1+2; 30–40 molecule pipeline, 3–4 FDA readouts next 8–12 months. Advanced materials ₹90 Cr adoption capex (Q2 FY'28 complete) to commercialize 4–5 lab-qualified products; 12-product pipeline.
— This quarter: beat
No separate management press release accompanied this filing beyond the regulatory board-outcome letter, so framing claims could not be cross-checked against company commentary; the relevant benchmark remains the FY27 margin band and CDMO targets from the Q1 concall, against which this quarter's 34.2% OPM is tracking at the top end. Public searches turned up no specific sell-side consensus estimate published for this exact quarter, so vsStreet is marked unknown rather than inferred — contemporaneous coverage had noted Q1 FY27 results "crushed Street estimates," and this quarter's growth cadence (revenue +57%, PAT +81% YoY) is broadly consistent with that trajectory continuing. The quarter also carried several corporate developments tying into the print: the board declared an ₹8/share interim dividend (400% of face value, record date November 5, 2026); the Honeywell HFC supply contract was extended to $590 Mn on October 29; and a subsidiary commissioned MPP debottlenecking capacity on September 29.
W1
OPM sustainability versus the 32-33%±1% FY27 guided band — now at 34.2%, the top edge of that range
W2
CDMO 3x asset-turn-by-FY29 progress and the 3-4 FDA readouts flagged for the next 8-12 months (per the August 2026 concall)
W3
Other income normalization — fell to ₹15.6 Cr from ₹35.1 Cr in Q1 — and whether NPM recovers toward Q1's 22.5%
Clean typed PDF, unambiguous columns; all totals reconcile exactly. No exceptional items this quarter in either period compared (nil at quarter level both years); FY26 full-year carried a ₹6.75 Cr consolidated / ₹6.93 Cr standalone labour-code exceptional provision, outside both compared quarters. Minor JV share-of-loss (₹0.01 Cr) reduces total profit for period to ₹269.23 Cr vs PAT line of ₹269.24 Cr — immaterial.
Margin beat + CDMO early, but capex makes this a Hold
Navin beat on EBITDA margins (34.2% vs. 32–33% guided) and posted 57% revenue growth, with CDMO USD100M target hit ahead of schedule. But the stock is priced at its all-time high, and near-term free cash flow faces a ₹700–1,000 crore annual capex siege. Long-term upside is not in doubt; near-term is a grind.
₹2,236 Cr
+51% YoY
₹513 Cr
+93% YoY
34.2%
beat 32–33% ±1% guidance
72 days
efficient working capital
Navin Fluorine delivered a genuinely strong H1: revenue raced ahead at 57% YoY growth in Q2, profit margins beat guidance by 66 basis points, and all three segments (HPP, Specialty Chemicals, CDMO) posted sequential and year-on-year momentum. The real tension is not whether the quarter was good — it was. The tension is whether this strong base is a stepping stone to the long-term upside (CDMO phase 2, Advanced Materials), or whether near-term free cash flow will drain under the weight of a ₹700–1,000 crore annual capex grind, while the stock sits nearly at its all-time high with valuations already baked in.
Where the margin beat came from
The 34.2% H1 EBITDA margin beat its 32–33% ±1% prior guidance. Management attributed this to three structural drivers, not a one-off tailwind: (1) operational leverage on a 51% H1 revenue ramp — fixed costs diluted; (2) capacity debottlenecking — MPP capacity commissioned in September 2026, R32 plant commissioning imminent, AHF utilization ramping at HPP; (3) pricing actions offsetting raw material inflation — HF, fluorspar, and sulfuric acid prices have risen, but pass-through contracts (Corteva, Soltice) and volume leverage held margins steady. Forex tailwind noted but positioned as a secondary factor. The operational efficiency lens is credible: a 57% revenue ramp with flat or lower-growth cost base is the classic margin-expansion recipe. However, this also signals that H2 normalization — if raw material tailwinds fade or pricing leverage compresses — could squeeze margins back toward guidance.
EBITDA margins 34.2%, beating guidance
SupportedH1 EBITDA margin 34.2% vs 32–33% ±1% prior guidance; OPM 34.2% sustained via operational efficiency (MPP debottlenecking, R32 ramp, AHF on play) + pricing actions offsetting cost inflation
CDMO USD100M run-rate target, achieved early
SupportedAchieved in Q2 on run-rate basis; management originally guided 'by FY27 end' — now flagged as arrived 2–3 quarters ahead of internal plan
All three segments delivered sequential growth
SupportedHPP (ref gas pricing advantage + Corteva/Soltice volumes), Specialty Chemicals (orchid business, Corteva growth, ₹350Cr+ targeting), CDMO (Fermion base + new molecule campaigns)
Gross profit resilience despite raw material inflation
SupportedOPM 34.2% held through pricing pass-through (contracts), volume leverage on 57% revenue ramp, and operational efficiency (not pricing alone or forex alone)
What changed on this call
Four material updates moved the dial: (1) Soltice HFO contract reset — extended from an original 4-year term to 11-year total visibility through 2032. Annual run-rate steps to USD45M vs. prior USD58M (pricing mechanism reflects market dynamics), but total potential jumps to USD180M on volume and pricing upside over the life of the deal. This is a strategic win: Soltice is the advanced-cooling play in a world moving away from HFC refrigerants. (2) CDMO inflection front-loaded — USD100M run-rate hit in Q2 (not by year-end as originally planned). Phase 2 cGMP-4 facility (₹125 crore capex) in progress; expected operational by end Q4 FY27. Once live, Navin targets ₹900–1,000 crore CDMO revenue by FY28–29 (3x asset turn on the Phase 1+2 capex base). (3) Specialty Chemicals now credibly targeted — management shifted from vague 'growth business' to a named ₹350 crore+ annual run-rate target by FY27 close. This signals confidence in product-market fit and pricing power in the chemicals franchise. (4) Capex frame quantified — ₹700–1,000 crore annually through FY28, split across Phase 2 cGMP-4 (₹125 Cr), Advanced Materials adoption capex (₹90 Cr to Q2 FY28), R32 ramp, and DRDO co-development projects. This is the capex grind that will pressure free cash flow.
Margin beat driven by operational efficiency (MPP debottlenecking, R32 ramp, AHF on play), not pricing windfall alone
CDMO USD100M target hit early; Phase 2 capex (₹125 Cr) in progress; 3–4 FDA readouts expected next 8–12 months
Soltice HFO contract extended 11 years (to 2032); USD180M potential on volume + pricing upside
Specialty Chemicals ₹350Cr+ target by FY27 end; broad-based segment growth (HPP, SC, CDMO all up)
Capex frame (₹700–1,000 Cr annually) will compress free cash flow through FY28; payback uncertain until Phase 2 revenue ramps
Customer concentration: HPP 60–65% of revenue; Corteva + Soltice ~40% of HPP; loss of either would be material
Raw material inflation (HF, fluorspar, sulfuric acid) could compress margins if pricing power weakens
Geopolitical volatility (Russia-Ukraine, Middle East) could disrupt supply chains and customer demand
Capex execution and near-term FCF pressure
High₹700–1,000 Cr annual capex through FY28 will drain liquidity; delays on Phase 2 or Advanced Materials could defer revenue scaling and valuation upside. Working capital normalizing post-H1 seasonal boost could further tighten near-term cash.
Customer concentration in HPP segment
Medium-highLoss of Corteva or Soltice could impact ₹400–500 Cr+ revenue (~40–50% of HPP). Mitigated by long-term contracts (Corteva to 2026, Soltice extended to 2032), but remains a structural concentration risk if end-markets weaken.
Raw material inflation compressing margins
MediumHF, fluorspar, sulfuric acid prices elevated. If pricing power weakens (end-market demand softens, competitive pressure rises, or pass-through contracts lag inflation), EBITDA margins could compress below 30%. Management's efficiency gains could be offset.
CDMO molecule FDA approval delays
Medium3–4 FDA readouts expected next 8–12 months are a key near-term catalyst. Regulatory delays beyond this window could push revenue scaling beyond FY28–29, deferring the Phase 2 capex payback and tightening near-term FCF further.
Geopolitical volatility disrupting supply and demand
MediumRussia-Ukraine, Middle East tensions could disrupt supply of HF, fluorspar, and other raw materials. Refrigerant demand is cyclical to global capex; geopolitical shocks could crimp end-market demand for industrial cooling products.
How the street is positioned: The stock closed at ₹8,845 on 2026-11-05, just 1.17% below its all-time high of ₹8,949.5, and is trading above all three key moving averages (SMA20 ₹8,322.3, SMA50 ₹8,414.5, SMA200 ₹7,284.68). RSI is neutral at 60.2, but volume is increasing — a sign of accumulation or validation of the move. Domestically, DIIs edged higher to 28.46% ownership in Q1 FY27 (vs. 27.62% in Q4 FY26), a positive signal of institutional confidence; FIIs are flat at 23.73% (vs. 23.78% prior), and promoters steady at 27.08%. The combination — near-ATH price, flat FII, rising DII, increasing volume — suggests the market has priced the CDMO inflection and margin beats. There is limited downside from current valuations on a base-case execution (CDMO phase 2 on time, FDA readouts not all negative). However, there is also limited near-term upside: long-term value creation (FY28–29 EBITDA expansion) is still 18–24 months away, and near-term FCF will be compressed by capex. A holder at current prices is essentially betting on flawless Phase 2 execution and positive FDA catalysts. For new entrants, the risk-reward is balanced to slightly unfavorable — the upside is known (CDMO ₹900–1,000 Cr revenue, Advanced Materials commercialization), but the near-term grind (capex, FCF pressure) is also very real.
1 · CDMO FDA readouts (Q3–Q4 FY27 and beyond)
Management expects 3–4 molecule FDA readouts over the next 8–12 months. Two are in advanced trial stage with positive interim results; one China-approved molecule is on a fast-track FDA pathway. Positive readouts would de-risk the CDMO revenue ramp and justify Phase 2 capex. Negative outcomes or delays beyond the 8–12 month window would compress long-term EBITDA assumptions and force a reset of near-term FCF projections.
2 · Phase 2 cGMP-4 commissioning (end Q4 FY27)
₹125 crore capex for Phase 2 dedicated CDMO facility; expected operational by end Q4 FY27. Full warehouse and ETP infrastructure to scale CDMO to ₹900–1,000 crore annual revenue by FY28–29. Any delay or cost overrun would extend the capex grind and defer cash generation. Track capex spend quarterly — if H2 FY27 capex exceeds the ₹350–400 Cr guidance run-rate, raise a red flag.
3 · Advanced Materials adoption capex and commercialization (Q2 FY28)
₹90 crore capex in progress; expected commissioning by Q2 FY28. Navin will commercialize 4–5 lab-qualified products into a pharma market of ₹400+ crore (+ dual-use defense potential per DRDO co-dev). Early order visibility is encouraging, but volume ramp risk is real. By Q2 FY28, expect data on first-tranche sales, order pipeline, and pricing confidence.
Navin Fluorine is executing on plan. The quarter hit EBITDA margin guidance and beat the consensus print. CDMO inflection is real and arrived ahead of schedule. What's changed is confidence and clarity — management named a Specialty Chemicals target (₹350Cr+), quantified capex (₹700–1,000 Cr annually), and extended Soltice visibility to 2032. That's all credible.
But the stock is at its all-time high and near-term free cash flow faces a capex siege through FY28. Long-term value creation — Phase 2 revenue ramp, Advanced Materials commercialization — is compelling but 18–24 months away. The verdict is Hold. Do not chase at current prices; wait for Phase 2 commissioning and the first FDA readouts to de-risk the thesis. If execution falters (capex balloons, FDA delays, raw material margins compress), valuation will reset sharply.
The number to track from here: organic free cash flow. If quarterly FCF remains deeply negative through H2 FY27 due to capex, or if management signals further capex additions, the near-term story shifts from 'grind' to 'strain.' Hold and wait for clarity.